MorphoSys AG buy FXX
Summary
This prediction ended on 09.03.22 with a price of €22.42. Massive losses of -72.98% were the result for the BUY prediction by FXX. FXX has 60% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | 1.056% | 1.056% | 18.108% | 16.006% |
iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% | 36.233% |
iShares Nikkei 225® | 2.553% | 4.359% | 17.676% | 10.955% |
iShares S&P 500 | -0.434% | 0.224% | 24.986% | 37.667% |
According to FXX what are the pros and cons of MorphoSys AG for the foreseeable future?
Pros
Cons
Comments by FXX for this prediction
In the thread Morphosys AG diskutieren
In the thread Trading Morphosys AG